480 related articles for article (PubMed ID: 11061579)
1. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
3. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
[TBL] [Abstract][Full Text] [Related]
4. The interaction of diltiazem with lovastatin and pravastatin.
Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
[TBL] [Abstract][Full Text] [Related]
5. Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats.
Dong J; Yu X; Wang L; Sun YB; Chen XJ; Wang GJ
Acta Pharmacol Sin; 2008 Oct; 29(10):1247-52. PubMed ID: 18817631
[TBL] [Abstract][Full Text] [Related]
6. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
8. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
9. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
[TBL] [Abstract][Full Text] [Related]
10. Effect of itraconazole on the pharmacokinetics of atorvastatin.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
[TBL] [Abstract][Full Text] [Related]
12. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR
Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
15. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
Sarich TC; Schützer KM; Dorani H; Wall U; Kalies I; Ohlsson L; Eriksson UG
J Clin Pharmacol; 2004 Aug; 44(8):928-34. PubMed ID: 15286097
[TBL] [Abstract][Full Text] [Related]
16. Lack of drug-drug interaction between cerivastatin and nifedipine.
Sachse R; Brendel E; Mück W; Rohde G; Ochmann K; Horstmann R; Kuhlmann J
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):409-13. PubMed ID: 9726692
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.
Neuvonen PJ; Jalava KM
Clin Pharmacol Ther; 1996 Jul; 60(1):54-61. PubMed ID: 8689812
[TBL] [Abstract][Full Text] [Related]
18. Effect of itraconazole on cerivastatin pharmacokinetics.
Kantola T; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 1999 Jan; 54(11):851-5. PubMed ID: 10027660
[TBL] [Abstract][Full Text] [Related]
19. Erythromycin coadministration increases plasma atorvastatin concentrations.
Siedlik PH; Olson SC; Yang BB; Stern RH
J Clin Pharmacol; 1999 May; 39(5):501-4. PubMed ID: 10234598
[TBL] [Abstract][Full Text] [Related]
20. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]